All News

Supplemental new drug application submitted to the FDA for the approval of darolutamide (Nubeqa) plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Exenatide (Byetta) is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Advil Sinus Congestion & Pain offers temporary relief of the symptoms associated with cold or flu, such as sinus pressure, headache, and fever.

The COVID-19 pandemic highlighted the importance of managing infections properly globally and the need for stewardship networks among partners.

Despite early excitement about the potential for pharmacists to prescribe COVID-19 oral antivirals, the program does not provide that ability.

A patient’s ability to pay for specialty medications will continue to be an issue because drug costs are prohibitive and add barriers to accessibility.

The risk of death from CVD was approximately 15% lower for those with the highest vegetable intake compared to the lowest vegetable intake.

Investigators advise third short for patients with weakened immune system, especially organ transplant recipients.

Although the risks are still, individuals with a history of migraines should be aware of and consult with their physicians, investigators say.

Pharmacists must understand the value of monitoring changes in quality of life and headache frequency to help facilitate the decision to continue, discontinue, or restart migraine prophylaxis.

Ten quiz questions to assess your knowledge on common treatments for heart failure.

Basaglar is indicated to improve glycemic control in adults and children with type 1 diabetes and adults with type 2 diabetes.

Loratadine (Alavert) is indicated for runny nose, sneezing, itchy and watery eyes, sinus pressure, and nasal congestion.

Epcoritamab is an investigational immunoglobulin G1-bispecific antibody being evaluated as a treatment for patients with follicular lymphoma in multiple clinical trials.

Enhanced tools in the field of structural biology may reveal new insights into HIV that could lead to a vaccine to protect against the virus progessing to AIDS.

Effectiveness is estimated at approximately 91% against any SARS-CoV-2 infection and approximately 85% effective against asymptomatic infection, analysis results show.

Experts David Pope, PharmD, and Christina Madison, PharmD, FCCP, AAHIVP, discussed the Biden Administration's new test-to-treat plan.

Important evidence about the health effects of e-cigarettes can help shape public health best practices in the United States, the findings of an analysis suggest.

This will increase Moderna’s vaccine catalog to 5, including vaccines against cytomegalovirus (CMV), Epstein-Barr virus (EBV), and HIV, in addition to the immunizations for HSV, and VZV.

Poziotinib demonstrates positive results for treatment-naïve patients with non-small cell lung cancer harboring HER2 exon 20 insertion mutations.

Ivosidenib in combination with azacitidine found to significantly improve event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia.

Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

OTC severe sinus medications offer relief to sinus headaches, help to loosen phlegm, reduces sinus pressure and chest congestions, and temporarily reduces fever

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the adverse events patients with ovarian cancer have reported during treatment with rucaparib.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how oncology pharmacy professionals can effectively address fatalistic beliefs and perceptions of cancer-related information among rural adults.

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Novel C. difficile infection (CDI) vaccine shows promise lowering the severity of CDI and in preventing medically attended CDI.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.